Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the ...

Orforglipron, a GLP-1 drug taken as a pill, achieved positive results in people with obesity and type 2 diabetes, although it ...

The pharma giant said amycretin led to weight loss and diabetes reductions in both injection and pill versions.

Vanda Pharmaceuticals’ expansion into the booming GLP-1 market has cleared a midphase test. | Vanda Pharmaceuticals’ ...

As competitive as the obesity drug market has become, Novo Nordisk's decision to slash the prices of its GLP-1 agonist drugs ...

Vanda Pharmaceuticals' tradipitant successfully reduced Wegovy-induced vomiting by 50% in a clinical trial. Phase 3 ...

An older oral version of the company's semaglutide drug failed to meet its main goal in late-stage trials testing whether the ...

Women who have rebound weight gain after stopping Wegovy or similar jabs end up gaining more weight during pregnancy, leading ...

The results show the treatment's potential to mitigate GLP-1 induced nausea and vomiting, which are key factors for those who stop using weight-loss drugs, Vanda Chief Executive Mihael Polymeropoulos ...

Until the end of March, Novo Nordisk will let people with prescriptions buy the first two doses of the drugs for $199 a month ...

Novo Nordisk announced on Monday that it is lowering costs for weight loss and diabetes drugs, weeks after it struck a deal ...